

Original article

EAACI/GA²LEN/EDF guideline: management of urticaria

This guideline is the result of a consensus reached during a panel discussion at the second International Consensus Meeting on Urticaria, *Urticaria 2004*, a joint initiative of the EAACI Dermatology Section and GA²LEN. Urticaria has a profound impact on the quality of life, and effective treatment is therefore required. The recommended first line treatment are nonsedating H₁ antihistamines. They have proven to be effective in double-blind controlled studies, but dosages increased up to fourfold over the recommended doses may be necessary. However, for different urticaria subtypes and in view of individual variation in the course of the disease and response to treatment, additional or alternative therapies may be required. Immunosuppressive drugs like cyclosporin A and corticosteroids are not recommended for long-term treatment due to unavoidable severe adverse effects. This guideline was, in addition, accepted by the European Dermatology Forum (EDF) and formally approved by the European Union of Medical Specialists (UEMS).

**T. Zuberbier¹, C. Bindslev-Jensen²,
W. Canonica³, C. E. H. Grattan⁴,
M. W. Greaves⁵, B. M. Henz¹,
A. Kapp⁶, M. M. A. Kozel⁷, M.
Maurer¹, H. F. Merk⁸, T. Schäfer⁹,
D. Simon¹⁰, G. A. Vena¹¹, B. Wedi⁶**

¹Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, Germany; ²Allergy Centre, Department of Dermatology, Odense University Hospital, Odense, Denmark; ³Allergy and Respiratory Diseases, DIMI – University of Genoa, Genoa, Italy; ⁴Dermatology Centre, Norfolk and Norwich University Hospital, Norwich, UK; ⁵Department of Dermatology, Singapore General Hospital, Singapore; ⁶Department of Dermatology and Allergology, Hannover Medical University, Hannover, Germany; ⁷Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; ⁸Department of Dermatology, University Hospital RWTH Aachen, Aachen, Germany; ⁹Institute of Social Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany; ¹⁰Department of Dermatology, University Hospital Bern, Bern, Switzerland; ¹¹Department MIDIM, Unit of Dermatology, University of Bari, Bari, Italy

Key words: consensus; SIGN; treatment guideline; urticaria; wheal.

Prof. Dr T. Zuberbier
Department of Dermatology and Allergy
Allergy Centre Charité
Charité Universitätsmedizin Berlin
Campus Mitte Schumannstr. 20/21
D-10117 Berlin
Germany

Accepted for publication 13 July 2005

This guideline is the result of a consensus reached during a panel discussion at the second International Consensus Meeting on Urticaria, *Urticaria 2004*, a joint initiative of the EAACI Dermatology Section and GA²LEN. The authors as members of the panel had prepared their suggestions regarding the treatment of urticaria in advance, based on the existing consensus paper of the first symposium in 2000 (1). These suggestions were then discussed in detail among the panel and with the participants of the meeting, and consensus was reached using a simple voting system. With over 400 participants

specialized in the field of urticaria from more than 20 countries, this consensus also includes any possible regional differences in therapeutic approach.

Although urticaria is elicited by a great diversity of factors and clinically presents in a highly variable way, its treatment follows the same principles. The therapy of urticaria is best subdivided into three basic lines of approach, which should be followed in each patient.

Avoidance elimination or treatment of the eliciting stimulus or cause

This approach is the most desirable since it is curative, but it is unfortunately not applicable in the majority of

Abbreviations: AH, antihistamine; ns, nonsedating; RCT, randomized controlled trial; s, sedating; sg, second generation.

patients as the exact eliciting stimulus is frequently unknown. It can however be instituted for the rare patients with IgE-mediated urticaria and for all patients with physical urticaria. In the latter group, the impact of physical stimuli can be diminished and symptoms ameliorated by appropriate measures (e.g. cushioning in pressure urticaria). In chronic urticaria treatment of associated infectious and/or inflammatory processes, including *Helicobacter pylori*-associated gastritis, parasitic diseases and cancer, or of food and drug intolerance can be curative or at least helpful.

Inhibition of mast cell mediator release

The next approach should be aimed at the mast cell as the central effector cell. Unfortunately, there are only few effective drugs available to inhibit mast cell mediator release.

Therapy of target tissues of mast cell mediators

Currently, the most frequently used therapy aims at inhibiting the effect of mast cell mediators on the target tissue and thus at the suppression of symptoms.

The specific treatment options in these three categories have been evaluated in this guideline.

Methods

Studies were evaluated using the Methodology Checklist 2 for Randomized Controlled Trials of the Scottish Intercollegiate Guidelines Network (SIGN) resulting in the following 3-level code: ++, +, -. This code, together with the study type, decided the Level of Evidence (1⁺⁺ to 1⁻, 2⁺⁺ to 2⁻, 3, and 4) that led to the Grade of Recommendation (A–D). Literature search was done using PubMed/MEDLINE and EMBASE, in part also hand-searching. Studies that had no English abstract or investigated primarily first generation antihistamines, e.g. diphenhydramine, hydroxyzine, acrivastine, and also terfenadine and astemizole, which are no longer recommended due to adverse effects, were excluded.

Eliciting stimuli

With this therapeutic approach, an exact diagnosis is a basic prerequisite. If remission on elimination or avoidance of the suspected agent occurs, recurrence of symptoms on re-exposure provides more proof of its causative nature since spontaneous remission of urticaria might also occur incidentally on elimination of a suspected cause.

Drugs

When such agents are suspected in the course of diagnosis, they should be omitted entirely or substituted

by another class of agents if indispensable. Drugs causing pseudoallergic reactions (the prototype being ASA) cannot only elicit, but also aggravate pre-existing chronic urticaria (2), so that elimination will only improve symptoms.

Physical stimuli

Avoidance of physical stimuli for the treatment of physical urticaria is desirable, but not always simple. Detailed information about the physical properties of the respective stimulus should make the patient sufficiently knowledgeable to recognize and control his exposure in normal daily life. Thus, it is important in demographic urticaria as well as in delayed pressure urticaria to point out that pressure is defined as force per area and that simple devices, such as broadening of the handle of heavy bags or reducing friction in case of demographic urticaria, may already be helpful in the prevention of symptoms. Similar considerations hold for cold urticaria. Here, the impact of the chill factor in cold winds needs to be remembered. For solar urticaria, the exact identification of the range of eliciting wavelengths may be important for the appropriate selection of sunscreens or for the selection of light bulbs with a UV-A filter. However, in many patients, the threshold for the individual eliciting stimulus is low and thus, total avoidance of symptoms is virtually impossible.

Eradication of infectious agents and treatment of inflammatory processes

In contrast to physical urticaria where coexisting, potentially disease-sustaining factors are only found in cold and demographic urticaria, chronic urticaria is often associated with a variety of inflammatory or infectious processes (3). This is regarded as significant in some instances. These infections include those of the gastrointestinal tract like *H. pylori* (4) or bacterial infections of the nasopharynx, which should be treated appropriately. Parasites, a rare cause of urticaria in industrial countries, should be eliminated (5). In the past, intestinal candidosis has been regarded as a highly important eliciting factor for chronic urticaria (6), but more recent findings fail to support a significant causative role (7). Nevertheless, it is recommended that massive candidosis should be treated.

Apart from infectious diseases, chronic inflammatory processes due to diverse other diseases have been identified as causative for urticaria in the recent past. This holds particularly for gastritis, reflux esophagitis or inflammation of the bile duct or bile gland (7, 8).

Removal of FcεRI autoantibodies

There is currently little experience in the treatment of chronic urticaria by removal of autoantibodies.

Plasmapheresis has been shown to be of temporary benefit in individual, severely affected patients (9, 10). Alternatively, immunological treatment with agents inhibiting antibody formation like cyclosporin as one of their actions (11–14) or high dose immunoglobulin infusions (15) have been proven to be helpful. Due to high costs, these therapies should be reserved for auto-antibody-positive chronic urticaria patients unresponsive to other forms of treatment.

Dietary management

IgE-mediated food allergy is rare in urticaria (7, 16). If identified, the specific food allergens need to be omitted as best as possible. In a subgroup of chronic urticaria patients pseudoallergic reactions to naturally occurring food ingredients and in some cases to food additives are seen (7, 16–18). In these cases a diet containing only low levels of natural as well as artificial food pseudo-allergens should be instituted and maintained for a prolonged period of at least 3–6 months. During this time spontaneous remission is achieved in approximately 50% of patients. It should be underlined that avoidance of type I – allergens clears urticaria symptoms within 24–48 h if relevant allergens are rapidly eliminated, whereas in pseudoallergy, a diet must often be maintained for 2–3 weeks before beneficial effects can be observed.

Mast cell directed therapy

At present, the most frequently used drugs inhibiting mast cell mediator release are corticosteroids. They should be avoided for long-term treatment of chronic urticaria, since dosages necessary to suppress symptoms are usually high with significant adverse effects. For acute urticaria, a short course of corticosteroids may however be helpful to reduce disease duration (19). Nevertheless, well-designed randomized controlled trials (RCT) are missing.

Cyclosporin A also has a moderate, direct effect on mast cell mediator release (20). Efficacy of cyclosporin A in combination with a nonsedating H₁ antihistamine has been shown in a RCT (level of evidence 2⁺⁺, grade of recommendation C, see Table 1), but this drug cannot be recommended as standard treatment due to a higher incidence of adverse effects.

PUVA reduces the numbers of mast cells in the upper dermis. It has been successfully used in mastocytosis and is helpful in treatment-resistant patients with this condition (21, 22). For the treatment of chronic urticaria, UV-A and UV-B treatment for 1–3 months can be added to the antihistamine treatment (23, 24).

Tolerance induction may also be considered under the heading of mast cell directed therapy. This is sometimes used for cold urticaria, cholinergic urticaria and solar

urticaria, where even a rush therapy with UVA has been proven to be effective within 3 days (25).

Therapy at the target organ

Nearly all symptoms of urticaria are primarily mediated by H₁-receptors located on nerves and endothelials. Thus, H₁-receptor antagonists are of eminent importance in the treatment of urticaria. With the availability of this group of substances since the 1950s, urticaria is one of the diseases that can be treated effectively with a very low adverse effect profile. The development of second generation, nonsedating or low-sedating antihistamines has allowed to improve the quality of life of urticaria patients. New generation antihistamines also exert anti-inflammatory effects such as cytokine release from basophils and mast cells (26, 27). This may be of additional benefit in controlling symptoms in urticaria if these effects occur at a clinically relevant dosage (28). There are some studies showing the benefit of a higher dosage of antihistamines in individual patients (29, 30), but further investigations in this field are necessary. The possibility of increased adverse cardiac effects, especially with terfenadine and astemizole (31), is a consideration in the choice of the specific antihistamine, especially when using higher dosages than recommended by the manufacturers. Further progress with regard to drug safety was achieved by the development of the new generation antihistamines fexofenadine and descarboxyloratadine, which are cytochrome P450 independent metabolites of earlier antihistamines. Levocetirizine is the active enantiomer of cetirizine, thus, where cetirizine is indicated as effective treatment, levocetirizine could also be considered. The highest reported accidental overdose of antihistamine (50-fold of the prescribed dosage of cetirizine in a 18-month-old boy) induced no adverse effects (32). The main drug interactions have been described until recently for sedating antihistamines in association with drugs affecting the central nervous system, like analgetics, hypnotics, sedatives, and mood elevating drugs as well as alcohol. MAO inhibitors can prolong and intensify anticholinergic effects. With the exception of cetirizine, levocetirizine, and fexofenadine, other modern antihistamines are also metabolized by cytochrome P450 enzymes (33). This interaction leads to increased plasma levels when there is concomitant treatment with drugs employing this enzyme system for metabolism such as ketoconazole or erythromycin. In the case of fexofenadine, there is an interaction with the GP system in the intestine, resulting in an increased plasma concentration in case of concomitant administration of ketokonazole or erythromycin.

In summary, considering their good safety profile, second-generation antihistamines must be considered as first line symptomatic treatment for urticaria (level of evidence 1⁺⁺, grade of recommendation A, see Table 1).

Table 1. Effective treatment in urticaria

Type of urticaria	Standard treatment	Methodological quality*	Level of evidence†	Grade of recommendation‡	Reference	Treatment for nonresponsive patients	Methodological quality*	Level of evidence†	Grade of recommendation‡	Reference
(a) Acute urticaria	Treatment recommended by the majority of the panel and the audience									
	ns sg H ₁ -AH	-	2 ⁻	D	(43)	Prednisone, 2 × 20 mg/day for 4 days	+	2 ⁺	D	(45)
	Loratadine	-	2 ⁻	D	(44)	Prednisolone, 50 mg/day for 3 days	-	2 ⁻	D	(43)
	Cetirizine	-	2 ⁻	D	(49, 50)	H ₂ -blocker, single dose or 5 day	+	2 ⁻	D	(46–48)
	Treatment recommended by the majority of the panel and the audience									
	ns sg H ₁ -AH	1 ⁺⁺	1 ⁺⁺	A	(51–61)	<i>Combination therapy</i>	++	2 ⁺⁺	C	(84)
	Azelastine	+	1 ⁻	D	(62–64)	ns sg H ₁ -AH and cyclosporin A	++	2 ⁺	D	(85–87)
	Cetirizine	++	1 ⁺	D	(65, 66)	ns sg H ₁ -AH and montelukast	+	2 ⁻	D	(88–91)
	Desloratadine	++	1 ⁺	D	(67–71)	ns sg H ₁ and H ₂ -AH cimetidine	+	2 ⁻	D	
	Ebastine	+	1 ⁻	D	(72, 73)	<i>Monotherapy</i>	+	2 ⁺	D	(92–94)
	Fexofenadine	++	1 ⁺	D	(74–76)	Tricyclic antidepressants (doxepin)	+	2 ⁺	D	(95)
	Levocetirizine	++	1 ⁺	D	(77–83)	Ketotifen	++	2 ⁺⁺	C	(96, 97)
	Loratadine	++	1 ⁺	D		Hydroxychloroquine	-	2 ⁻	D	
Mizolastine	++	1 ⁺	D		Dapsone	No RCT	3	D		
Increase dosage if necessary up to fourfold		3	C		Sulfasalazine	No RCT	3	D		
					Methotrexate	No RCT	3	D		
					Corticosteroids	No RCT	4	D		
					Other treatment options					
(b) Chronic urticaria	Treatment recommended by the majority of the panel and the audience									
	ns sg H ₁ -AH and stanazolol	++	2 ⁺	D	(98)	<i>Combination therapy</i>	++	2 ⁺	D	(98)
	ns sg H ₁ -AH and zafrlukast	-	2 ⁻	D	(100–102)	<i>Monotherapy</i>	-	2 ⁻	D	(103)
	Oxatomide	-	2 ⁻	D	(104, 105)	Nifedipine	-	2 ⁻	D	(106, 107)
	Nifedipine	-	2 ⁻	D		Leukotriene antagonists:				
	Montelukast	-	2 ⁻	D		Montelukast	-	2 ⁻	D	
	Warfarin	-	2 ⁻	D		Warfarin	-	2 ⁻	D	
	Interferon	No RCT	3	D		Interferon	No RCT	3	D	
	Plasmapheresis	No RCT	3	D		Plasmapheresis	No RCT	3	D	
	Immunoglobulins	No RCT	3	D		Immunoglobulins	No RCT	3	D	
	Azathioprine	No RCT	3	D		Azathioprine	No RCT	3	D	
	Climate therapy					Climate therapy				
	UV light treatment					UV light treatment				
					Ketotifen (see also chronic urticaria)	+	2 ⁻	D	(109)	
(c) Physical urticaria	Always consider avoidance of stimuli									
	Treatment recommended by the majority of the panel and the audience									
	ns sg H ₁ -AH	+	2 ⁻	D	(108)	<i>Combination therapy</i>	+	2 ⁻	D	(111)
Cetirizine	+	2 ⁺	D	(110)	Montelukast and ns H ₁ -AH (loratadine)	+	2 ⁻	D	(112)	
Treatment recommended by the majority of the panel and the audience					<i>Monotherapy</i>					
ns sg H ₁ -AH	-	2 ⁻	D		Prednisone 40–20 mg	-	2 ⁻	D		
Cetirizine	No RCT	3–4	D		Dapsone	No RCT	3	D		

Table 1. Continued

Cold urticaria	Treatment recommended by the majority of the panel and the audience	++	B	(114–117)						
	ns sg H1-AH (overall)		2 ⁺							
	Loratadine									
	Cetirizine									
	Mizolastine									
	Desloratadine									
	Other treatment options									
	Combination therapy									
	Ketotifen and nimesulide	–						2 ⁻	D	(112)
	Monotherapy									
Solar urticaria	Clobetasol prop. 0.5% ointment	+						2 ⁻	D	(113)
	Methotrexate	No RCT						3	D	
	Sulfasalazine	No RCT						3	D	
	Trial with penicillin i.m./p.o.	No RCT						3	D	
	Trial with doxycycline p.o.	No RCT						3	D	
	Induction of physical tolerance									
	Other treatment options									
	Cyproheptadine	+						2 ⁻	D	(118)
	Ketotifen	+						2 ⁺	D	(119)
	Montelukast	No RCT						3	D	
(d) Special types of urticaria	Induction of physical tolerance cyclosporine A							3	D	
	Other treatment options									
	Plasmapheresis							3	D	
	Plasmapheresis + PUVA							3	D	
	Photopheresis							3	D	
	Plasma exchange							3	D	
	IVIGs							3	D	
	Hydroxychloroquine							4	D	
	‘Exercise tolerance’									
	Other treatment options									
Cholinergic urticaria	Ketotifen	+						2 ⁻	D	(109)
	Danazol	+						2 ⁻	D	(124)
	ns H1-AH									
Cholinergic urticaria	Treatment recommended by the majority of the panel and the audience									
	ns H1-AH									
	Cetirizine	–						2 ⁻	D	(120)
Cholinergic urticaria	ns H1-AH									
	Cetirizine	+						2	D	(122)
	Increase dosage if necessary	++						2 ⁺	D	(123)

*Rating of methodological quality of the study or review according to the Methodology Checklist 2: Randomized Controlled Trials of the Scottish Intercollegiate Guidelines Network (SIGN), ++, All or most of the criteria have been fulfilled. Where they have not been fulfilled, the conclusions of the study or review are thought very unlikely to alter; +, Some of the criteria have been fulfilled. Those criteria that have not been fulfilled or adequately described are thought unlikely to alter the conclusions; –, Few or no criteria have been fulfilled. The conclusions of the study are thought likely or very likely to alter. †The grade of recommendation according to SIGN criteria: 1⁺⁺, High quality meta analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias; 1⁺, Well conducted meta analyses, systematic reviews of RCTs, or RCTs with a low risk of bias; 1⁻, Meta analyses, systematic reviews of RCTs, or RCTs with a high risk of bias; 2⁺⁺, High quality systematic reviews of case-control or cohort or studies. High quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal; 2⁺, Well conducted case control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability that the relationship is causal; 2⁻, Case control or cohort studies with a high risk of confounding, bias, or chance and a significant risk that the relationship is not causal; 3, Nonanalytic studies, e.g. case reports, case series; 4, Expert opinion; ‡The level of evidence provided by the study is derived from the code allocated for the methodological quality and the type of study, according to the Methodology Checklist 2: Randomized Controlled Trials of the Scottish Intercollegiate Guidelines Network (SIGN). A, At least one meta analysis, systematic review, or RCT rated as 1⁺⁺, and directly applicable to the target population; or a systematic review of RCTs or a body of evidence consisting principally of studies rated as 1⁺, directly applicable to the target population, and demonstrating overall consistency of results; B, A body of evidence including studies rated as 2⁺⁺, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2⁺, directly applicable to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2⁺⁺, D, Evidence level 3 or 4; or extrapolated evidence from studies rated as 2⁻.

Before considering alternative treatment, higher dosages up to a fourfold increase should be used (level of evidence 3, grade of recommendation C, see Table 1). Up to date, well-designed RCTs comparing efficacy and safety of different nonsedating H₁-antihistamines in chronic urticaria are missing. The data available implicate that the differences are marginal, although different individual responses to nonsedating H₁ antihistamines are accepted as expert opinion.

Further therapeutic possibilities

While antihistamines at higher dosages will control symptoms in the majority of patients with urticaria, alternative treatments are needed for the remaining unresponsive patients.

Since the severity of urticaria may fluctuate, and since spontaneous remission may occur at any time, it is recommended to re-evaluate the necessity for continued or alternative drug treatment every 3–6 months.

Many of the alternatives such as combinations of nonsedating H₁ antihistamines with H₂ antihistamines or with antileukotrienes are based on RCTs with low levels of evidence (Table 1). The same holds true for monotherapy with ketotifen, montelukast, warfarin, and hydroxychloroquine. In addition, evidence from older data investigating oxatomide, doxepin, and nifedipine is poor.

For dapsone, sulfasalazine, methotrexate, interferon, plasmapheresis, and immunoglobulins only

uncontrolled trials or case series have been published (Table 1).

Recent RCTs addressed antileukotrienes (Tables 1 and 2). Studies are difficult to compare due to different populations (e.g. inclusion of only aspirin and food additive intolerant patients or exclusion of autologous serum skin test positive patients).

On the other hand, some treatment alternatives formerly proposed have been shown to be ineffective in double-blind, placebo controlled studies and should no longer be used (although grade of recommendation is low). These include tranexamic acid and sodium cromoglycate (DNCG) in chronic urticaria (34, 35), nifedipin in dermographic urticaria (36) and colchicine and indomethacin in delayed pressure urticaria (37, 38).

Table 1 summarizes the consensus of the current standard drug treatment and alternatives in several subtypes of urticaria, whereas Table 2 summarizes ineffective drugs in controlled trials.

Taken together, grade A recommendations exist only for symptomatic therapy with nonsedating antihistamines. However, it should be considered that these drugs are insufficient in several patients with urticaria and that RCTs often included patients with mild to moderate disease only. In contrast, most alternatives have been tested in patients previously not responding to antihistamines.

Thus, we clearly need more and well-designed RCTs to recommend or refuse potential alternatives.

Table 2. Studies with drugs showing no significant effect on urticaria

Type of urticaria	Ineffective treatment	Methodological quality*	Level of evidence†	Grade of recommendation‡	Reference
(a) Chronic urticaria	sH ₁ -AH and H ₂ -AH cimetidine	–	2 [–]	D	(89)
	sH ₁ -AH and β-sympathomimetic terbutaline	–	2 [–]	D	(125, 126)
	Leukotriene antagonist montelukast	++	2 ⁺	D	(85)
	Addition of montelukast to nsH ₁ -AH (Desloratadine)	++	2 ⁺	D	(85)
	Leukotriene antagonist zafirlukast	++	2 ⁺	D	(127)
	Tranexamic acid (cyclokapron)	–	2 [–]	D	(128)
	Cromolyn	–	2 [–]	D	(129)
(b) Physical urticaria					
	Delayed pressure urticaria	Colchicine	+	2 [–]	D
	Indomethacin	+	2 [–]	D	(131)
Demographic urticaria	Addition of H ₂ -AH to sH ₁ -AH or nsH ₁ -AH	+	2 [–]	D	(132, 133)
	Nifedipine	+	2 [–]	D	(134)

*Rating of methodological quality of the study or review according to the Methodology Checklist 2: Randomized Controlled Trials of the Scottish Intercollegiate Guidelines Network (SIGN).

†The level of evidence provided by the study is derived from the code allocated for the methodological quality and the type of study, according to the Methodology Checklist 2: Randomized Controlled Trials of the Scottish Intercollegiate Guidelines Network (SIGN).

‡The grade of recommendation according to SIGN criteria.

++, All or most of the criteria have been fulfilled. Where they have not been fulfilled, the conclusions of the study or review are thought very unlikely to alter; +, Some of the criteria have been fulfilled. Those criteria that have not been fulfilled or adequately described are thought unlikely to alter the conclusions; –, Few or no criteria have been fulfilled. The conclusions of the study are thought likely or very likely to alter; 2⁺, Well conducted case control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability that the relationship is causal; 2[–], Case control or cohort studies with a high risk of confounding, bias, or chance and a significant risk that the relationship is not causal; D, Evidence level 3 or 4; or extrapolated evidence from studies rated as 2⁺.

Quality of life

Health Related Quality of Life (HRQoL) parameter is presently recognized as a primary outcome in clinical trials, population studies and public health. Both physicians and researchers are aware that it is nowadays a need, rather than a simple option. The assessment of this parameter allows to complete the traditional assessment based on biomedical and socio-economic data in order to obtain a global evaluation of both disease and treatment.

While HRQoL has been extensively assessed in numerous dermatological conditions, a literature search shows that only few studies evaluate this topic in patients with chronic urticaria. The available data indicate that chronic urticaria has a detrimental effect on both objective functioning and subjective well being. For example, O'Donnell et al. showed that health status scores in patients with chronic urticaria are comparable to those reported from patients with coronary artery disease (39). Furthermore, both health status and subjective satisfaction in patients with chronic urticaria is lower than in healthy subjects and in patients with respiratory allergy (40). A study of Poon et al. focuses on the extent and nature of disability in different types of chronic urticaria, showing a large variation in HRQoL scores within different urticarial subsets (41).

In these mentioned studies, the assessment of HRQoL was performed by using generic questionnaires (applicable to all health conditions) and by specialty specific questionnaire (developed for skin diseases). There is only one disease specific questionnaire applied in patients with chronic urticaria, but it has not been validated (39).

Recently a questionnaire specifically developed for chronic urticaria has been validated, including physical, emotional, social and practical aspects that characterize this condition (42). The aim was to offer the research community a sensible and simple tool to evaluate specifically HRQoL in urticaria patients. This new tool named Chronic Urticaria Quality of Life Questionnaire (CU-Q₂oL) was generated and tested following well-established procedures and applied to other similar instruments. The CU-Q₂oL met the standards for

validity with good construct validity, internal consistency, reliability, and responsiveness. These psychometric characteristics make the new questionnaire adapted for the assessment of the specific burden of both chronic urticaria and its treatment on HRQoL.

Conclusion

The quality of life in urticaria is severely affected and management of the disease should therefore be prompt and in close cooperation between patient and physician. Due to high variability of disease severity, an individual approach is necessary for each patient. As a first line, triggering factors should be avoided as far as possible and any associated diseases should be treated. In the majority of patients, symptomatic pharmacological treatment is possible with new generation antihistamines, with a very low adverse effect profile and good patient compliance. In nonresponding patients, higher dosages (up to fourfold) and alternative medication should be tried. Most of these, such as corticosteroids or cyclosporin, should be reserved for severely affected patients because of their unfavorable adverse effect profile.

Acknowledgments

This guideline was generated in cooperation with the German Urticaria Patient Association 'Patientenkreis Urtikaria' (Head: Frau Heidrun Martin, Idstein, Germany). The Global Allergy and Asthma European Network (GA²LEN) and the EAACI Dermatology section have provided institutional and logistic support and like to thank the European Center for Allergy Research Foundation (ECARF) for organizing and financing the symposium and the publication of this guideline. ECARF is a nonprofit foundation administered by the Stifterverband für die Deutsche Wissenschaft (Donors' Association for the Promotion of the German Sciences and Humanities) with its office at the Department of Dermatology and Allergy at the Charité – Universitätsmedizin Berlin (see <http://www.ecarf.org>). ECARF is funded mainly by private donations; for parts of the funding of the symposium, ECARF has received an educational grant by UCB Farchim. The authors like to thank Ilaria Baiardini for her contribution on the issue of quality of life in urticaria patients. Formal approval of the guideline by the UEMS was obtained through the Section of Dermatology in May 2005.

References

- Zuberbier T, Greaves MW, Juhlin L, Merk H, Stingl G, Henz BM. Management of urticaria – a consensus report. *J Invest Dermatol Symp Proc* 2001;**6**:128–131.
- Wüthrich B. Adverse reactions to food additives. *Ann Allergy* 1993;**71**:379–384.
- Wedi B, Raap U, Kapp A. Chronic urticaria and infections. *Curr Opin Allergy Clin Immunol* 2004;**4**:387–396.
- Wedi B, Kapp A. Helicobacter pylori infection in skin diseases: a critical appraisal. *Am J Clin Dermatol* 2002;**3**:273–282.
- Henz BM, Zuberbier T. Causes of urticaria. In: Henz BM, Zuberbier T, Grabbe J, Monroe E, editors. *Urticaria*. Clinical, diagnostic and therapeutic aspects. Berlin: Springer, 1998:19–38.
- Champion RH, Roberts SOB, Carpenter RG, Roger JH. Urticaria and angio-oedema. A review of 554 patients. *Br J Dermatol* 1969;**81**:588–597.
- Zuberbier T, Chantraine-Hess S, Hartmann K, Czarnetzki BM. Pseudo-allergen-free diet in the treatment of chronic urticaria. *Acta Derm Venereol (Stockh)* 1995;**75**:484–487.

8. Bruno G, Andreozzi P, Graf U. Exercise-induced urticaria – angioedema syndrome: a role in gastroesophageal reflux. In: Vena GA, Puddu P, editors. *Proceedings of the International Symposium on Urticaria*. Bari: Publ Scientif., 1998;85–89.
9. Grattan CEH, Francis DM, Slater NGP, Barlow RJ, Greaves MW. Plasmapheresis for severe unremitting chronic urticaria. *Lancet* 1992;**339**:1078–1080.
10. Greaves M. Chronic urticaria. *J Allergy Clin Immunol* 2000;**105**:664–672.
11. Grattan CEH, O'donnell BFO, Francis DM, Niimi N, Barlow RJ, Seed PT et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. *Br J Dermatol* 2000;**143**:365–372.
12. Barlow RJ, Black AK, Greaves MW. Treatment of severe chronic urticaria with cyclosporin A. *Eur J Dermatol* 1993;**3**:273–275.
13. Fradin MS, Ellis CN, Goldfarb MT, Voorhees JJ. Oral cyclosporin for severe chronic idiopathic urticaria and angioedema. *J Am Acad Dermatol* 1991;**25**:1065–1067.
14. Toubi E, Blant A, Kessel A, Golan TD. Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. *Allergy* 1997;**52**:312–316.
15. O'donnell BF, Barr RM, Black AK, Francis DM, Kermani F, Niimi N et al. Intravenous immunoglobulin in autoimmune chronic urticaria. *Br J Dermatol* 1998;**138**:101–106.
16. Juhlin L. Recurrent urticaria: clinical investigation of 330 patients. *Br J Dermatol* 1981;**104**:369–381.
17. Pfrommer C, Bastl R, Vieths S, Ehlers I, Henz BM, Zuberbier T. Characterization of naturally occurring pseudoallergens causing chronic urticaria. *J Allergy Clin Immunol* 1996;**97**:367.
18. Pigatto PD, Valsecchi RH. Chronic urticaria: a mystery. *Allergy* 2000;**55**:306–308.
19. Zuberbier T, Iffländer J, Semmler C, Czarnetzki BM. Acute urticaria – clinical aspects and therapeutical responsiveness. *Acta Derm Venereol (Stockh)* 1996;**76**:295–297.
20. Stellato C, De Paulis A, Ciccarelli A, Cirillo R, Patella V, Casolaro V et al. Anti-inflammatory effect of cyclosporin A on human skin mast cells. *J Invest Dermatol* 1992;**98**:800–804.
21. Godt O, Proksch E, Streit V, Christophers E. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. *Dermatology* 1997;**195**:35–39.
22. Horio T. Indications and action mechanisms of phototherapy. *J Dermatol Sci* 2000;**23**(Suppl. 1):S17–S21.
23. Hannuksela M, Kokkonen EL. Ultraviolet light therapy in chronic urticaria. *Acta Derm Venereol* 1985;**65**:449–450.
24. Olafsson JH, Larko O, Roupe G, Granerus G, Bengtsson U. Treatment of chronic urticaria with PUVA or UVA plus placebo: a double-blind study. *Acta Dermatol Res* 1986;**278**:228–231.
25. Beissert S, Stander H, Schwarz T. UVA rush hardening for the treatment of solar urticaria. *J Am Acad Dermatol* 2000;**42**:1030–1032.
26. Lippert U, Krüger-Krasagakes S, Möller A, Kiessling U, Czarnetzki BM. Pharmacological modulation of IL-6 and IL-8 secretion by the H₁-antagonist descarboethoxy-loratadine and dexamethasone from human mast and basophilic cell lines. *Exp Dermatol* 1995;**4**:272–276.
27. Lippert U, Möller A, Welker P, Artuc M, Grützkau A, Henz BM. Inhibition of cytokine secretion from human mast cells and basophils by H₁- and H₂-receptor antagonists. *Exp Dermatol* 2000;**9**:118–124.
28. Merk H, Sauer RR, Steigleder GK. Histamine release in cold urticaria – effect of ketotifen and oxatomide. In: Champion RH, Greaves MW, Kobza-Black A, Pye RJ, editors. *The urticarias*. London: Churchill Livingstone, 1985:222–223.
29. Zuberbier T, Münzberger CH, Haustein U, Trippas E, Mariz SD, Czarnetzki BM. Double-blind crossover study of high dose cetirizine in cholinergic urticaria. *Dermatology* 1996;**193**:324–327.
30. Kontou-Fili K, Maniakatou G, Demaka P, Paleologos G. Therapeutic effect of cetirizine 2HCl in delayed pressure urticaria. *Health Sci Rev* 1989;**3**:23–25.
31. Lindquist M, Edwards R. Risks of non-sedating antihistamines. *Lancet* 1997;**349**:1322.
32. Ridout SM, Tariq SM. Cetirizine overdose in a young child. *J Allergy Clin Immunol* 1997;**99**:860–861.
33. Renwick AG. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. *Clin Exp Allergy* 1999;**29**(Suppl. 3):116–124.
34. Thormann J, Laurberg G, Zachariae H. Oral sodium cromoglycate in chronic urticaria. *Allergy* 1980;**35**:139–141.
35. Laurberg G. Tranexamic acid (Cyklok- apron) in chronic urticaria: a double-blind study. *Acta Derm Venereol* 1977;**57**:369–370.
36. Lawlor F, Ormerod AD, Greaves MW. Calcium antagonist in the treatment of symptomatic dermographism. Low-dose and high-dose studies with nifedipine. *Dermatologica* 1988;**177**:287–291.
37. Lawlor F, Black AK, Ward AM, Morris R, Greaves MW. Delayed pressure urticaria, objective evaluation of variable disease using a dermatographometer and assessment of treatment using colchicine. *Br J Dermatol* 1989;**120**:403–408.
38. Dover JS, Kobza-Black A, Ward AM, Greaves MW. Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients. *J Am Acad Dermatol* 1988;**18**:1289–1298.
39. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. *Br J Dermatol* 1997;**136**:197–201.
40. Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. *Allergy* 2003;**58**:621–623.
41. Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of disability on different urticarial conditions. *Br J Dermatol* 1999;**140**:667–671.
42. Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerru L, Compalati E et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). *Allergy* 2005;**60**:1073–1078.
43. Zuberbier T, Iffländer J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. *Acta Derm Venereol* 1996;**76**:295–297.
44. Simons FER. Prevention of acute urticaria in young children with atopic dermatitis. *J Allergy Clin Immunol* 2001;**107**:703–706.
45. Pollack CV, Romano TJ. Outpatient management of acute urticaria: the role of prednisone. *Ann Emerg Med* 1995;**26**:547–551.
46. Watson NT, Weiss EL, Harter PM. Famotidine in the treatment of acute urticaria. *Clin Exp Dermatol* 2000;**25**:186–189.
47. Pontasch MJ, White LJ, Bradford JC. Oral agents in the management of urticaria: patient perception of effectiveness and level of satisfaction with treatment. *Ann Pharmacother* 1993;**27**:730–731.
48. Moscati RM, Moore GP. Comparison of cimetidine and diphenhydramine in the treatment of acute urticaria. *Ann Emerg Med* 1990;**19**:12–15.

49. Camarasa JM, Aliaga A, Fernandez-Vozmediano JM, Fonseca E, Iglesias L, Tagarro I. Azelastine tablets in the treatment of chronic idiopathic urticaria. Phase III, randomised, double-blind, placebo and active controlled multicentric clinical trial. *Skin Pharmacol Appl Skin Physiol* 2001;**14**:77–86.
50. Henz BM, Metzner P, O'keefe E, Zuberbier T. Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses. *Allergy* 1998;**53**:180–183.
51. La Rosa M, Leonardi S, Marchese G, Corrias A, Barberio G, Oggiano N et al. Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. *Ann Allergy Asthma Immunol* 2001;**87**:48–53.
52. Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. *J Dermatolog Treat* 2004;**15**:55–57.
53. Lambert D, Hantzperg M, Danglas P, Bloom M. Double-blind comparative study of terfenadine and cetirizine in chronic idiopathic urticaria. *Allergy Immunol (Paris)* 1993;**25**:235–240.
54. Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. *Ann Pharmacother* 1996;**30**:1075–1079.
55. Breneman D, Bronsky EA, Bruce S, Kalivas JT, Klein GL, Roth HL et al. Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial. *J Am Acad Dermatol* 1995;**33**:192–198.
56. Andri L, Senna GE, Betteli C, Giovanni S, Andri G, Lombardi C et al. A comparison of the efficacy of cetirizine and terfenadine. A double-blind, controlled study of chronic idiopathic urticaria. *Allergy* 1993;**48**:358–365.
57. Goh CL, Wong WK, Lim J. Cetirizine vs placebo in chronic idiopathic urticaria—a double blind randomised crossover study. *Ann Acad Med Singapore* 1991;**20**:328–330.
58. Juhlin L. Cetirizine in the treatment of chronic urticaria. *Clin Ther* 1991;**13**:81–86.
59. Alomar A, De La C, Fernandez J. Cetirizine vs astemizole in the treatment of chronic idiopathic urticaria. *J Int Med Res* 1990;**18**:358–365.
60. Kalivas J, Breneman D, Tharp M, Bruce S, Bigby M. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. *J Allergy Clin Immunol* 1990;**86**:1014–1018.
61. Juhlin L, Arendt C. Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine. *Br J Dermatol* 1988;**119**:67–71.
62. Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. *J Am Acad Dermatol* 2003;**48**:535–541.
63. Monroe EW. Desloratadine for the treatment of chronic urticaria. *Skin Therapy Lett* 2002;**7**:1–2, 5.
64. Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. *Int J Dermatol* 2001;**40**:72–76.
65. Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. *Drugs* 1996;**52**(Suppl. 1):30–34.
66. Peyri J, Vidal J, Marrón J, Fonseca E, Suárez E, Ledo A et al. Ebastine in chronic urticaria: a double-blind placebo-controlled study. *J Dermatolog Treat* 1991;**2**:51–53.
67. Degonda M, Pichler WJ, Bircher A, Helbling A. Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients. *Schweiz Rundsch Med Prax* 2002;**91**:637–643.
68. Kawashima M, Harada S, Tango T. Review of fexofenadine in the treatment of chronic idiopathic urticaria. *Int J Dermatol* 2002;**41**:701–706.
69. Kawashima M, Harada S. Efficacy and safety of fexofenadine HCl in Japanese patients with chronic idiopathic urticaria. *Int Arch Allergy Immunol* 2001;**124**:343–345.
70. Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. *Ann Allergy Asthma Immunol* 2000;**84**:517–522.
71. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. *J Am Acad Dermatol* 2000;**43**:24–30.
72. Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind placebo-controlled, parallel, multicenter study. *Int J Dermatol* 2005; DOI: 10.1111/j.1365-4632.2005.02609.
73. Kapp A, Wedi B. Chronic urticaria: clinical aspects, and focus on a new antihistamine, levocetirizine. *J Drugs Dermatol* 2004;**3**:632–639.
74. Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. *Clin Ther* 1992;**14**:17–21.
75. Belaich S, Bruttman G, Degreef H, Lachapelle JM, Paul E, Pedrali P et al. Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. *Ann Allergy* 1990;**64**:191–194.
76. Monroe EW, Fox RW, Green AW, Izuno GT, Bernstein DI, Pleskow WW et al. Efficacy and safety of loratadine (10 mg once daily) in the management of idiopathic chronic urticaria. *J Am Acad Dermatol* 1988;**19**:138–139.
77. Kapp A, Guinépain MT, Lachapelle JM, Murrieta-Aguttes M. Mizolastine in the treatment of chronic urticaria: a European clinical experience with 2452 patients managed in daily practice (PANEOS CU Study). In: Marone G, editor. *Clinical immunology and allergy in medicine*. Naples: JGC Editions, 2003.
78. Leynadier F, Duarte-Risselin C, Murrieta M. Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URILOR study group. *Eur J Dermatol* 2000;**10**:205–211.
79. Lorette G, Giannetti A, Pereira RS, Leynadier F, Murrieta-Aguttes M. One-year treatment of chronic urticaria with mizolastine: efficacy and safety. UR-TOL study group. *J Eur Acad Dermatol Venereol* 2000;**14**:83–90.
80. Dubertret L, Murrieta AM, Tonet J. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. *J Eur Acad Dermatol Venereol* 1999;**12**:16–24.
81. Ring J, Brockow K, Ollert M, Engst R. Antihistamines in urticaria. *Clin Exp Allergy* 1999;**29**(Suppl. 1):31–37.
82. Lachapelle JM, Tennstedt D, Murrieta M. Comparative efficacy and safety of mizolastine 10 mg o.d. versus placebo in chronic idiopathic urticaria. *Allergy* 1998;**53**:57.
83. Brostoff J, Fitzharris P, Dunmore C, Theron M, Blondin P. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. *Allergy* 1996;**51**:320–325.

84. Grattan CE, O'Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. *Br J Dermatol* 2000;**143**:365–372.
85. Di Lorenzo G, Pacor ML, Mansueto P, Pellitteri ME, Lo Bianco C, Ditta V et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. *J Allergy Clin Immunol* 2004;**114**:619–625.
86. Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. *Clin Exp Allergy* 2004;**34**:1401–1407.
87. Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. *J Allergy Clin Immunol* 2002;**110**:484–488.
88. Bleehe SS, Thomas SE, Greaves MW, Newton J, Kennedy CT, Hindley F et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. *Br J Dermatol* 1987;**117**:81–88.
89. Diller G, Orfanos CE. Management of idiopathic urticaria with H1 + H2 antagonists. A crossover double blind long-term study. *Z Hautkr* 1983;**58**:785–793.
90. Harvey RP, Wegs J, Schocket AL. A controlled trial of therapy in chronic urticaria. *J Allergy Clin Immunol* 1981;**68**:262–266.
91. Monroe EW, Cohen SH, Kalbfleisch J, Schulz CI. Combined H1 and H2 antihistamine therapy in chronic urticaria. *Arch Dermatol* 1981;**117**:404–407.
92. Goldsobel AB, Rohr AS, Siegel SC, Spector SL, Katz RM, Rachelefsky GS et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. *J Allergy Clin Immunol* 1986;**78**:867–873.
93. Greene SL, Reed CE, Schroeter AL. Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. *J Am Acad Dermatol* 1985;**12**:669–675.
94. Harto A, Sendagorta E, Ledo A. Doxepin in the treatment of chronic urticaria. *Dermatologica* 1985;**170**:90–93.
95. Kamide R, Niimura M, Ueda H, Imamura S, Yamamoto S, Yoshida H et al. Clinical evaluation of ketotifen for chronic urticaria: multicenter double-blind comparative study with clemastine. *Ann Allergy* 1989;**62**:322–325.
96. Reeves GEM, Boyle MJ, Bonfield J, Dobson P. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. *Int Med J* 2004;**34**:182–186.
97. Baumgart KW, Mullins R. Use of hydroxychloroquine in refractory urticaria. *J Allergy Clin Immunol* 2000;**105**:795–796.
98. Parsad D, Pandhi R, Juneja A. Stan-ozolol in chronic urticaria: a double blind, placebo controlled trial. *J Dermatol* 2001;**28**:299–302.
99. Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. *J Allergy Clin Immunol* 2004;**113**:134–140.
100. Beck HI, Cramers M, Herlin T, Sondergaard I, Zachariae H. Comparison of oxatomide and clemastine in the treatment of chronic urticaria. A double blind study. *Dermatologica* 1985;**171**:49–51.
101. Demaubeuge J, Tennstedt D, Broux R. Does mast cell protection plus mediator antagonism surpass the effect of a classic antihistaminic in the treatment of chronic urticaria? A double-blind comparison of oxatomide and mequitazine. *Dermatologica* 1982;**164**:386–394.
102. Peremans W, Mertens RL, Morias J, Campaert H. Oxatomide in the treatment of chronic urticaria. A double-blind placebo-controlled trial. *Dermatologica* 1981;**162**:42–50.
103. Bressler RB, Sowell K, Huston DP. Therapy of chronic idiopathic urticaria with nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled, crossover trial. *J Allergy Clin Immunol* 1989;**83**:756–763.
104. Nettis E, Dambra P, D'oronzio L, Loria MP, Ferrannini A, Tursi A. Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. *Arch Dermatol* 2001;**137**:99–100.
105. Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. *Clin Exp Allergy* 2001;**31**:1607–1614.
106. Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angioedema. *Clin Exp Allergy* 2000;**30**:1161–1165.
107. Barlow RJ, Greaves MW. Warfarin in the treatment of chronic urticaria/angio-edema. *Br J Dermatol* 1992;**126**:415–416.
108. Sharpe GR, Shuster S. The effect of cetirizine on symptoms and wealing in dermatographic urticaria. *Br J Dermatol* 1993;**129**:580–583.
109. Cap JP, Schwanz HJ, Czarnetzki BM. Effect of ketotifen in urticaria factitia and urticaria cholinergica in a crossover double-blind trial. *Hautarzt* 1985;**36**:509–511.
110. Kontou-Fili K, Maniatakou G, Demaka P, Gonianakis M, Palaiologos G, Aroni K. Therapeutic effects of cetirizine 2HCl in delayed pressure urticaria: clinicopathologic findings. *J Am Acad Dermatol* 1991;**24**:1090–1093.
111. Nettis E, Pannofino A, Cavallo E, Ferrannini A, Tursi A. Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria. *J Allergy Clin Immunol* 2003;**112**:212–213.
112. Vena GA, D'argento V, Cassano N, Mastrolonardo M. Sequential therapy with nimesulide and ketotifen in delayed pressure urticaria. *Acta Derm Venereol (Stockh)* 1998;**78**:304–305.
113. Barlow RJ, Macdonald DM, Black AK, Greaves MW. The effects of topical corticosteroids on delayed pressure urticaria. *Arch Dermatol Res* 1995;**287**:285–288.
114. Juhlin L. Inhibition of cold urticaria by desloratadine. *J Dermatolog Treat* 2004;**15**:51–59.
115. Bonadonna P, Lombardi C, Senna G, Canonica GW, Passalacqua G. Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. *J Am Acad Dermatol* 2003;**49**:714–716.
116. Dubertret L, Pecquet C, Murrieta-Aguttes M, Leynadier F. Mizolastine in primary acquired cold urticaria. *J Am Acad Dermatol* 2003;**48**:578–583.
117. Villas MF, Contreras FJ, Lopez Cazana JM, Lopez Serrano MC, Martinez AF. A comparison of new non-sedating and classical antihistamines in the treatment of primary acquired cold urticaria (ACU). *J Investig Allergol Clin Immunol* 1992;**2**:258–262.

118. Wanderer AA, St Pierre PJ, Ellis EF. Primary acquired cold urticaria. Double-blind comparative study of treatment with cyproheptadine, chlorpheniramine, and placebo. *Arch Dermatol* 1977;**113**:1275–1277.
119. St Pierre JP, Kobric M, Rackham A. Effect of ketotifen treatment on cold-induced urticaria. *Ann Allergy* 1985;**55**:840–843.
120. Roelandts R. Diagnosis and treatment of solar urticaria. *Dermatol Ther* 2003;**16**:52–56.
121. Bilslund D, Ferguson J. A comparison of cetirizine and terfenadine in the management of solar urticaria. *Photodermatol Photoimmunol Photomed* 1991;**8**:62–64.
122. Zuberbier T, Aberer W, Burtin B, Rihoux JP, Czarnetzki BM. Efficacy of cetirizine in cholinergic urticaria. *Acta Derm Venereol* 1995;**75**:147–149.
123. Zuberbier T, Munzberger C, Hausteiner U, Trippas E, Burtin B, Mariz SD et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. *Dermatology* 1996;**193**:324–327.
124. Wong E, Eftekhari N, Greaves MW, Ward AM. Beneficial effects of danazol on symptoms and laboratory changes in cholinergic urticaria. *Br J Dermatol* 1987;**116**:553–556.
125. Harvey RP, Wegs J, Schocket AL. A controlled trial of therapy in chronic urticaria. *J Allergy Clin Immunol* 1981;**68**:262–266.
126. Spangler DL, Vanderpool GE, Carroll MS, Tinkelman DG. Terbutaline in the treatment of chronic urticaria. *Ann Allergy* 1980;**45**:246–247.
127. Reimers A, Pichler C, Helbling A, Pichler WJ, Yawalkar N. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. *Clin Exp Allergy* 2002;**32**:1763–1768.
128. Laurberg G. Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study. *Acta Derm Venereol* 1977;**57**:369–370.
129. Thormann J, Laurberg G, Zachariae H. Oral sodium cromoglycate in chronic urticaria. *Allergy* 1980;**35**:139–141.
130. Lawlor F, Black AK, Ward AM, Morris R, Greaves MW. Delayed pressure urticaria, objective evaluation of a variable disease using a dermatographometer and assessment of treatment using colchicine. *Br J Dermatol* 1989;**120**:403–408.
131. Dover JS, Black AK, Ward AM, Greaves MW. Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients. *J Am Acad Dermatol* 1988;**18**:1289–1298.
132. Sharpe GR, Shuster S. In dermatographic urticaria H2 receptor antagonists have a small but therapeutically irrelevant additional effect compared with H1 antagonists alone. *Br J Dermatol* 1993;**129**:575–579.
133. Matthews CN, Boss JM, Warin RP, Storari F. The effect of H1 and H2 histamine antagonists on symptomatic dermatographism. *Br J Dermatol* 1979;**101**:57–61.
134. Lawlor F, Ormerod AD, Greaves MW. Calcium antagonist in the treatment of symptomatic dermatographism. Low-dose and high-dose studies with nifedipine. *Dermatologica* 1988;**177**:287–291.